Targets › HIV1
3 programs from 1 company in 3 trials: 3 Phase 1; Infectious disease; next expected readout Dec 2027.
Open in Phaseline: the race on HIV1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | DV201P-RNA mRNA encoding HIV-1 Env gp150 transmembrane trimers to induce V2 apex-directed broadly neu | HIV1 | Phase 1 | HIV | Dec 2027 |
| National Institute of Allergy and Infectious Diseases (NIAID) | DV202B1-RNA mRNA encoding HIV-1 Env gp150 transmembrane trimers to induce V2 apex-directed broadly neu | HIV1 | Phase 1 | HIV | Dec 2027 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Ad4-Env150KN Adenovirus serotype 4 vector expressing HIV-1 envelope protein | HIV1 | Phase 1 | Healthy Volunteer | Nov 2028 |
HIV (2) Healthy Volunteer (1)
protein or peptide (3)
National Institute of Allergy and Infectious Diseases (NIAID) (3)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.